[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surgical-resection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surgical-resection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100570637","meningioma-and-embolism-thrombosis-risk--investigation-of-coagulation-100570637",false,"NCT06709833","Meningioma and Embolism Thrombosis Risk & Investigation of Coagulation","001_2024_BO2","Inclusion Criteria:\n\n* Patients undergoing resection for meningioma or\n* Patients undergoing resection for glioma or\n* Healthy controls\n* written consent for study participation\n\nExclusion Criteria:\n\n\\-",true,"ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","Despite being generally benign tumors, meningiomas are associated with an increased risk for thrombembolic complications after surgical resection. The molecular mechanisms underlying this circumstance are still unknown.\n\nIn this prospective observational trial, the investigators aim to evaluate the changes in coagulation and platelet function caused by tumor resection.\n\nBlood samples are obtained by patients undergoing meningioma resection before and immediately after resection to detect said changes.\n\nAs a control cohort, blood samples are obtained from patients undergoing resection for glioma.",[25,26,27],"Meningeoma","Thrombembolism","Surgical Resection",[29,30,31],"meningeoma","thrombembolism","tissue-factor","RECRUITING","2025-01-03",{"date":35,"type":36},"2025-01-06","ACTUAL",{"date":38,"type":36},"2024-12-16",{"date":40,"type":21},"2026-08-31",{"name":42,"class":43},"University Hospital Tuebingen","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":44},"100558176","primary-tumor-resection-for-m1a-stage-lung-cancer-100558176","NCT06547710","Primary Tumor Resection for M1a Stage Lung Cancer","Primary Tumor Resection for M1a Stage Lung Cancer With Occult Pleural Dissemination Discovered During Surgery: a Prospective, Single-arm, Multi-center, Phase Ⅱ Trial","ECTOP-1023","Inclusion Criteria:\n\n1. Volunteer to participate in clinical research, willing to follow and able to complete all trial procedures;\n2. Aged 18-80 years (including critical values) when signing the informed consent form;\n3. ECOG score 0 or 1;\n4. No previous lung cancer surgery;\n5. Intraoperative or postoperative pathological confirmation of M1a stage lung cancer;\n6. Occult pleural metastasis found during surgery;\n7. Preoperative lymph node staging is cN0;\n8. First-time treatment and no radiotherapy or chemotherapy.\n\nExclusion Criteria:\n\n1. The lesion cannot be completely removed surgically;\n2. Cytological or histological pathology confirms other lung malignancies other than lung cancer;\n3. Patients who have undergone lung cancer surgery before;\n4. Patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.","75 Years",{"count":55,"type":21},66,"This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1023. This study aims to explore the safety and efficacy of primary lesion resection in the treatment of M1a stage lung cancer with pleural dissemination found during surgery, and to more accurately evaluate whether primary lesion resection can improve the OS and quality of life of the corresponding patients.",[58,27],"Lung Cancer Metastatic","2024-08-07",{"date":61,"type":36},"2024-08-09",{"date":63,"type":36},"2024-04-01",{"date":65,"type":21},"2026-06",{"name":67,"class":43},"Fudan University",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":94},"100201423","phase-2-safety-and-efficacy-study-using-5-ala-oral-administration-as-an-adjuvant-therapy-on-the-rate-of-local-tumor-recurrence-in-patients-who-have-desmoids-tumors-100201423","NCT01898416","Safety and Efficacy Study Using 5-ALA Oral Administration as an Adjuvant Therapy on the Rate of Local Tumor Recurrence in Patients Who Have Desmoids Tumors","A PHASE 2, SINGLE CENTRE, SINGLE ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF 5- ALA POHOTODYNAMIC THERAPY AS ADJUVANT THERAPY AFTER SURGICAL DISSECTION IN PATIENTS WITH DESMOID TUMORS.","Inclusion Criteria:\n\n1. Patient has a resectable histologically confirmed desmoid tumor.\n2. Previously treated (by chemotherapy, irradiation or surgery) patients are eligible.\n3. Age \\> 18 years\n4. Signed informed consent prior to patient recruitment. -\n\nExclusion Criteria:\n\n1. Hepatic enzymes or bilirubin \\> 2X upper limit of normal.\n2. Serum creatinine \\> 2.5 x upper limit of normal.\n3. Suspected \u002Fdocumented metastatic disease.\n4. Active or uncontrolled infections.\n5. Active second malignant disease (excluding non-melanoma skin cancer, or in situ cervix or breast carcinoma) \\\u003C 2 years prior to the study.\n6. Use of other investigational agents \\\u003C 30 days prior to the study.\n7. Patients who are mentally or physically unable to comply with all aspects of the study.\n8. Any serious medical condition, including the presence of laboratory abnormalities, which places the subject at an unacceptable risk if he or she participates in this study or confounds the experimental ability to interpret data from the study.\n9. Pregnant or lactating females.\n10. Known intolerance or allergy to 5-ALA\n11. Suspicious or documented acute or chronic porphyria",{"count":76,"type":21},140,"INTERVENTIONAL",[79],"PHASE2","The purpose of this study is to evaluate the efficacy of preoperative 5-ALA oral administration and subsequently intraoperative tumor bed phototherapy with red light laser, as an adjuvant therapy on the 3 years rate of local tumor recurrence in patients with desmoid tumors. To evaluate the Safety of 5-ALA administration. 5 years local recurrence rate.",[82,83,27],"The Aim of the Study is to Evaluate the Efficacy of Photodynamic Therapy as an","Adjuvant Therapy on the Clinical Outcome of Patients With Desmoid Tumors After","2013-10-30",{"date":86,"type":21},"2013-10-31",{"date":88,"type":4},"2013-06",{"date":90,"type":21},"2026-12",{"name":92,"class":93},"michal roll","OTHER_GOV",2]